Deciphera Pharmaceuticals, Inc. (DCPH) [Rocket]

Overview

Deciphera Pharmaceuticals, Inc. (DCPH)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/04/2023	4	Sherman Matthew L (EVP & Chief Medical Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
08/09/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/09/2023	8-K	Quarterly results
08/03/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/12/2023	4	Friedman Franklin Stuart (Director) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
05/03/2023	S-3ASR	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/03/2023	10-Q	Quarterly Report for the period ended March 31, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	134.0	96.1	42.1	25.0	0.0	0.0	0.0	0.0
Revenue growth	39.4%	128.5%	68.3%
Cost of goods sold	8.8	2.9	0.2	0.0	0.0	0.0	0.0	0.0
Gross profit	125.3	93.2	41.9	25.0	0.0	0.0	0.0	0.0
Gross margin	93.5%	97.0%	99.5%	100.0%
Selling, general and administrative	120.2	136.3	114.1	68.1	21.2
Research and development	187.8	257.0	199.0	157.6	82.9	39.5	20.2	12.5
General and administrative						11.4	5.7	5.1
EBIT	-182.7	-300.1	-271.2	-200.7	-104.1	-50.9	-25.8	-17.6
EBIT margin	-136.3%	-312.1%	-644.4%	-802.9%
Pre-tax income	-178.2	-300.0	-266.5	-192.3	-99.9	-50.3	-25.9	-19.8
Income taxes	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-178.9	-300.0	-266.5	-192.3	-99.9	-50.3	-25.9	-19.8
Net margin	-133.5%	-312.0%	-633.2%	-769.0%

Diluted EPS	($2.37)	($5.16)	($4.78)	($4.48)	($2.82)	($2.99)	($2.23)	($4.67)
Shares outstanding (diluted)	75.5	58.1	55.8	42.9	35.4	16.8	11.6	4.2

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.